Nicotinamide phosphoribosyltransferase (Nampt) converts nicotinamide into nicotinamide mononucleotide (NMN), which is subsequently converted to NAD+ by NMN adenyltransferase. Cancer cells commonly have an unusually high rate of NAD+ turnover, suggesting that inhibition of Nampt might selectively target cancer cells. STF-118804 is a small molecule inhibitor of Nampt (IC50s = 3-6 nM) that prevents NAD+ synthesis from nicotinamide.{24585} It inhibits the viability of multiple B-cell acute lymphoblastic leukemia (B-ALL) cell lines with nanomolar potency and induces apoptosis in MV4-11 cells.{24585} At 50 mg/kg for 20 days, STF-118804 has been shown to improve survival in an orthotopic xenotransplant model of high-risk ALL in mice.{24585} It has also been shown to target leukemia stem cells.{24585}
Productname
STF-118804
15283-50
By filling out this form, you are placing an order by e-mail. You will receive an order confirmation within one working day. The order cannot be modified after receipt of the order confirmation.
Productname
STF-118804
15283-50
By filling out this form, you request a sample. You will receive an order confirmation within one working day. The order cannot be modified after receipt of the order confirmation.
Are you looking for specific products, alternatives or documentation?